Tirzepatide

Tirzepatide (Zepbound) is indicated for:

• Adults with obesity.
• Adults with excess weight and weight-related medical problems.
• Adults with type 2 diabetes (marketed as Mounjaro).

• Individuals with a history of pancreatitis.
• Those under 18 years of age.
• Breastfeeding individuals.
• Patients with type 1 diabetes.
• Pregnant or planning-to-be pregnant individuals.
• Individuals or families with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Common side effects, usually mild-to-moderate, include:

• Nausea and vomiting
• Diarrhea
• Stomach pain
• Constipation
• Fatigue

Tirzepatide is FDA-approved for weight loss under the brand name Zepbound. It is also approved for managing type 2 diabetes under the brand name Mounjaro.

When using Tirzepatide, it may take a few weeks before you begin to notice changes in your appetite and weight. Initially, your doctor will prescribe a low starting dose, gradually increasing it over the next several weeks and months to minimize side effects while optimizing weight loss.

Many individuals start to see weight loss within a few weeks, but the rate of weight loss varies depending on factors such as your initial weight, changes in your daily habits (including calorie intake and physical activity), and any underlying conditions you may have.

Our Tirzepatide dosing:

• 2.5 mg dose
• 5 mg dose
• 7.5 mg dose
• 10 mg dose

While compounded medications, including tirzepatide, must adhere to strict standards set by the United States Pharmacopeia-National Formulary (USP-NF) and source their ingredients from FDA-registered facilities, the final products themselves are not reviewed by the FDA. This regulatory gap, combined with the potential for non-sterile conditions and lack of professional guidance, underscores the significant risks associated with using compounded tirzepatide.

To determine if Tirzepatide is right for you, our providers will review a simple questionnaire. Basic recommendations include:

• An initial BMI of 30 or greater.
• An initial BMI of 27 to 29.9 with at least one additional weight-related health issue (e.g., high blood pressure, high cholesterol, triglycerides, diabetes, or pre-diabetes).